FDA Approves Relacorilant for Ovarian, Fallopian, and Peritoneal Cancer

Publisher: The Insight Partners

The U.S. Food and Drug Administration approved relacorilant in combination with nab-paclitaxel, offering a new treatment option for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The approval represents a major advancement for patients whose disease progressed after one to three prior treatment regimens, including bevacizumab, providing hope for improved outcomes in a population with historically limited options.

The FDA based its decision on data from the randomized, multicenter ROSELLA trial (NCT05257408), which enrolled 381 patients with platinum-resistant disease. In the study, the addition of relacorilant, a selective glucocorticoid receptor antagonist, to nab-paclitaxel improved both progression-free and overall survival compared with nab-paclitaxel alone, demonstrating a statistically significant benefit.

Median progression-free survival for patients receiving the relacorilant-nab-paclitaxel combination reached 6.5 months versus 5.5 months in the chemotherapy-only arm, with a hazard ratio of 0.70, indicating a substantial reduction in the risk of disease progression. Moreover, median overall survival improved to 16.0 months compared with 11.9 months for those treated with nab-paclitaxel alone, highlighting the therapy’s potential impact on extending patient lives.

Ovarian cancer remains a significant health concern in the United States. About 20,890 new cases of ovarian cancer are expected in the U.S. in 2025, with 12,730 related deaths. This represents roughly 1.0% of all new cancer cases and approximately 2.1% of all cancer deaths in the country, emphasizing the urgent need for effective therapies for advanced and resistant disease.

The ROSELLA trial excluded patients requiring frequent or chronic glucocorticoid use, given relacorilant’s mechanism as a glucocorticoid receptor blocker. This precaution ensured patient safety and reliable trial results while demonstrating the drug’s clinical benefit in the intended population.

The FDA label also includes important safety information and contraindications. Relacorilant should not be used in patients dependent on corticosteroids for life-saving purposes, and clinicians must monitor for neutropenia, severe infections, adrenal insufficiency, and embryo-fetal toxicity. Such guidance is critical for safely combining relacorilant with chemotherapy.

The recommended dosing schedule calls for relacorilant at 150 mg orally once daily on the day before, the day of, and the day after each nab-paclitaxel infusion cycle. Nab-paclitaxel is administered intravenously at 80 mg/m² on Days 1, 8, and 15 of each 28-day cycle. This regimen is designed to optimize therapeutic synergy while maintaining tolerability.

Experts explain that relacorilant blocks cortisol-mediated signaling, potentially enhancing patient response to chemotherapy by reversing stress-induced resistance mechanisms. Cortisol has been linked to promoting tumor resistance by suppressing apoptotic pathways, and inhibiting its receptor may improve cancer cell sensitivity to treatment.

Industry analysts praised the approval, noting that relacorilant’s success in a platinum-resistant population expands precision oncology options. The FDA granted approval nearly 3.5 months ahead of the goal date, reflecting its commitment to therapies addressing high unmet medical needs.

Healthcare professionals emphasize close monitoring during treatment. The most commonly reported adverse reactions included decreased hemoglobin and neutrophils, fatigue, nausea, diarrhea, rash, and loss of appetite. These events underscore the importance of supportive care and careful dose adjustments.

Patient advocacy groups also welcomed the approval, highlighting that the relacorilant-nab-paclitaxel combination provides a critical option for patients whose cancers historically demonstrate resistance to standard chemotherapy. By expanding the therapeutic toolkit, this approval may improve survival and quality of life for many adults facing these aggressive cancers.

Researchers continue to explore additional applications for glucocorticoid receptor antagonists like relacorilant in resistance-mediated tumors. Ongoing studies aim to refine dosing, identify biomarkers of response, and expand its clinical utility.

As clinicians integrate relacorilant into practice, they must consider prior treatments, comorbidities, and potential adverse effects. Overall, the FDA approval represents a meaningful advance in addressing platinum-resistant ovarian, fallopian tube, and peritoneal cancers, providing renewed hope for patients and families.